Skip to content

CYPH CYPH Research And Development Incentive Income

Research And Development Incentive Income at other companies

Replimune Group logo
Replimune GroupREPL
$2.96M-3.6%
Replimune Group logo
Replimune GroupREPL
$341K-9.3%
Replimune Group logo
Replimune GroupREPL
-$1.63M-473%
PVL
Palvella TherapeuticsPVLA
$0-100%
VAN
Vivani MedicalVANI
$43K+155%
VAN
Vivani MedicalVANI
$685K+291%

Other financials

Income statement

See full
Revenue$375.0K
Operating income-$4.8M+69.7%
Net income-$77.2M-400%
EPS (diluted)-$0.46-24.3%

Balance sheet

See full
Cash & equivalents$6.7M-79.6%
Total debt$38.0K-75.3%
Total equity$84.4M+305%
Total assets$87.4M+151%

Cash flow

See full
Operating cash flow-$3.4M+76.3%

Valuation

See full
Market cap$65.19M-54.5%
Enterprise value$58.54M
P/S43.5×

Profitability

See full
Operating margin-2,761.7%
Net margin-2,705.8%

Returns & leverage

See full
Return on equity-108.2%-34.4pp
Debt / equity0.0×
Current ratio27.3×+24.9×

Where this comes from

Reported directly by CYPH in its filing.

Tagged under the XBRL concept cyph:ResearchAndDevelopmentIncentiveIncome.

The official record: CYPH’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CYPH's research and development incentive income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CYPH's research and development incentive income?
CYPH (CYPH) reported research and development incentive income of $0 in Q1 2026.
What does research and development incentive income mean?
This represents government grants, tax credits, or subsidies received specifically to offset the costs of research and development initiatives. It serves as a contra-expense that reduces the net burden of innovation spending on the income statement. Tracking this helps analysts understand how much of the company's R&D strategy is supported by external public or private funding.